Evaluation of MT Family Isoforms as Potential Biomarker for Predicting Progression and Prognosis in Gastric Cancer
Table 3
The prognostic values of MT isoforms in GC patients with different clinical stage (Kaplan-Meier plotter).
MT family
clinical stage
OS
PPS
cases
HR
95%CI
P value
cases
HR
95%CI
P value
MT1E
I
67
0.43
0.16-1.16
0.085
31
0.1
0.02-0.71
0.007
II
140
0.63
0.32-1.23
0.17
105
0.6
0.26-1.35
0.21
III
305
0.72
0.54-0.96
0.026
142
0.7
0.45-1.1
0.12
IV
148
0.72
0.46-1.14
1.14
104
1.3
0.84-2.07
0.22
MT1F
I
67
0.27
0.1-0.72
0.005
31
0.1
0.02-0.69
0.006
II
140
0.54
0.27-1.08
0.075
105
0.6
0.27-1.41
0.25
III
305
0.66
0.49-0.88
0.004
142
0.7
0.44-1.03
0.068
IV
148
0.7
0.44-1.11
0.12
104
1.3
0.77-2.25
0.31
MT1G
I
67
2.87
0.92-8.96
0.058
31
6.6
6.25-34.15
0.011
II
140
1.69
0.88-3.23
0.11
105
2
0.79-5.24
0.13
III
305
1.68
1.26-2.23
4E-04
142
2
1.29-3.02
0.001
IV
148
1.78
1.16-2.73
0.007
104
2.4
1.46-3.97
4E-04
MT1H
I
67
2
0.71-5.57
0.18
31
0.2
0.02-1.79
0.12
II
140
0.54
0.28-1.04
0.061
105
0.5
0.25-1.07
0.07
III
305
0.75
0.57-1.01
0.054
142
0.7
0.45-1.04
0.076
IV
148
0.62
0.41-0.95
0.027
104
1.3
0.74-2.1
0.41
MT1M
I
67
2.34
0.67-8.23
0.17
31
2.8
0.55-14.59
0.2
II
140
0.82
0.44-1.52
0.52
105
0.7
0.37-1.42
0.35
III
305
0.73
0.52-1.02
0.067
142
0.7
0.45-1.11
0.13
IV
148
0.73
0.46-1.15
0.17
104
1.5
0.92-2.32
0.11
MT1X
I
67
0.29
0.1-0.8
0.011
31
0
—
0.002
II
140
0.49
0.22-1.11
0.081
105
0.6
0.29-1.33
0.22
III
305
0.61
0.46-0.81
7E-04
142
0.6
0.39-0.92
0.017
IV
148
0.66
0.45-0.99
0.041
104
1.4
0.79-2.35
0.27
MT2A
I
67
0.35
0.13-0.93
0.028
31
0.1
0.02-0.67
0.005
II
140
0.57
0.28-1.16
0.12
105
0.6
0.27-1.43
0.26
III
305
0.79
0.59-1.05
0.11
142
0.7
0.47-1.16
0.19
IV
148
0.78
0.51-1.18
0.24
104
1.5
0.93-2.27
0.095
MT3
I
67
1.79
0.61-5.21
0.28
31
3.5
0.76-16.1
0.089
II
140
2.07
1.14-3.74
0.014
105
2
0.99-3.82
0.049
III
305
2.05
1.48-2.83
1E-05
142
2.1
1.35-3.22
7E-04
IV
148
1.38
0.89-2.14
0.14
104
0.6
0.35-0.93
0.023
MT4
I
67
1.87
0.69-5.04
0.21
31
2.7
0.32-23.29
0.34
II
140
1.3
0.62-2.71
0.49
105
1.7
0.81-3.7
0.15
III
305
1.88
1.41-2.52
2E-05
142
1.9
1.21-2.95
0.004
IV
148
1.29
0.88-1.91
0.19
104
1.3
0.81-2.04
0.29
Notes: P value was analyzed using the survival analysis test. The fold indicates that the difference was statically significant. The P value was set up at 0.05. Abbreviations: GC: gastric cancer; OS: overall survival; PPS: postprogression survival; HR: hazard ratio.
